Fig. 5

Involvement of bradykinin on MT-II-induced articular hyperalgesia. MT-II (10 μg/joint) or PBS (vehicle) was injected in tibio-tarsal articulation (25 μL). Pain threshold was determined using a modified electronic pressure-meter test 8 h after MT-II injection, and represented as force (in g). (a) A bradykinin B₂ receptor antagonist icatibant (HOE 140, 0.75 μmol) or (b) a bradykinin B₁ receptor antagonist Lys-(Des-Arg⁹,Leu⁸)-bradykinin (des, 10 and 40 nmol) was injected by intra-articular route 20 min prior to MT-II. Each point represents the mean ± SEM of six animals. ***p < 0.001 indicate statistically significant differences when compared with control group (vehicle + vehicle). ###p < 0.001 indicate statistically significant differences when compared with MT-II group (MT-II + vehicle)